tulisokibart

Tulisokibart is a humanized monoclonal antibody that targets tumor necrosis factor-like cytokine 1A (TL1A), also known as TNF superfamily member 15. TL1A is implicated in the pathogenesis of several immune-mediated inflammatory diseases, including ulcerative colitis and Crohn’s disease. By binding to both soluble and membrane-bound TL1A, tulisokibart inhibits inflammatory pathways and may reduce intestinal fibrosis, potentially altering disease progression in inflammatory bowel disease (IBD). Tulisokibart has shown efficacy in inducing clinical remission in patients with moderately to severely active ulcerative colitis who have failed conventional or advanced therapies. It is being developed for multiple indications, including ulcerative colitis, Crohn’s disease, and systemic sclerosis-associated interstitial lung disease (SSc-ILD). The drug is administered intravenously or subcutaneously[1][3][5][6].

Brand names

Tulisokibart

Other names

anti-TL1A monoclonal antibodyanti-TL-1A monoclonal antibodyanti-TL 1A monoclonal antibody